Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.63 |
| ▸ | CTSS | P25774 | 3/20 | 0.63 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22371978 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345617 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371977 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7018649 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL15671593 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345607 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371979 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL59323 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL467994 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL256794 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549130-B | Liquid phase synthesis method of breast enlarging peptide | 武汉桀升生物科技有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | claimed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | claimed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | claimed |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | ZEVRA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | UNIV PENNSYLVANIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-09-16 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250122180-A1 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4529460-A1 | <SMALLCAPS/>? ? ?MOLLUSCUM CONTAGIOSUM? ? ? ? ?INHIBITORS OFINFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119486732-A | Molluscum contagiosum infection inhibitor and method of use thereof | 宾夕法尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-1990005141-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUKOCYTIC ELASTASE AND COLLAGENASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-05-17 | — | — | WO | disclosed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | disclosed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | TBK1, EIF2AK2, ITCH | CTSK 998/4885CTSS 1541/4885PSENEN 4155/4885 |
| US-20250122180-A1 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | SLC1A2, BDNF, OPRM1 | CTSK 3663/4885CTSS 2532/4885PSENEN 2580/4885 |
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, PCSK7, PCSK6 | CTSK 32/4885CTSS 309/4885PSENEN 3871/4885 |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | OPRM1, OPRD1, OPRK1 | CTSK 4223/4885CTSS 3646/4885PSENEN 1427/4885 |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | CTSK 2626/4885CTSS 2081/4885PSENEN 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.